Segall Bryant & Hamill, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Segall Bryant & Hamill, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $371,060 - $482,620	2,000 New	2,000 $475,000
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $277,080 - $464,000	2,000 New	2,000 $400,000
Q2 2021 Aug 12, 2021	SELL	$128.63 - $176.89 $1,157 - $1,592	-9 Reduced 0.45%	2,000 $339,000
Q3 2020 Nov 13, 2020	BUY	$121.19 - $165.49 $1,090 - $1,489	9 Added 0.45%	2,009 $292,000
Q4 2019 Feb 11, 2020	BUY	$74.51 - $124.23 $149,020 - $248,460	2,000 New	2,000 $230,000
Q2 2018 Aug 08, 2018	SELL	$88.31 - $107.8 $176,620 - $215,600	-2,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $145,060 - $236,540	2,000	2,000 $0

643

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.6B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.